BIOLASE, Inc. (NASDAQ:BIOL) has a beta value of 2.06 and has seen 1,309,916 shares traded in the recent trading session. The company, currently valued at $23.12 Million, closed the recent trade at $0.4553 per share which meant it lost $0 on the day or -3.88% during that session. The BIOL stock price is -354.65% off its 52-week high price of $2.07 and 53.88% above the 52-week low of $0.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.19 Million shares traded. The 3-month trading volume is 5.67 Million shares.

The consensus among analysts is that BIOLASE, Inc. (BIOL) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.17.

BIOLASE, Inc. (NASDAQ:BIOL) trade information

Despite being -3.77% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jun 24 when the BIOL stock price touched $0.529 or saw a rise of 12.85%. Year-to-date, BIOLASE, Inc. shares have moved -16.59%, while the 5-day performance has seen it change -11.33%. Over the past 30 days, the shares of BIOLASE, Inc. (NASDAQ:BIOL) have changed 15.28%. Short interest in the company has seen 1.35 Million shares shorted with days to cover at 0.24.

Wall Street analysts have a consensus price target for the stock at $2.38, which means that the shares’ value could jump 422.73% from current levels. The projected low price target is $1.65 while the price target rests at a high of $3.5. In that case, then, we find that the current price level is +668.72% off the targeted high while a plunge would see the stock lose 262.4% from current levels.

BIOLASE, Inc. (BIOL) estimates and forecasts

Figures show that BIOLASE, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -2.53% over the past 6 months, with this year growth rate of -16.88%, compared to -11.5% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -30.8% and -8.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be -37%.

3 analysts offering their estimates for the company have set an average revenue estimate of $2.09 Million for the current quarter. 3 have an estimated revenue figure of $6.57 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $8.64 Million and $9.49 Million respectively for this quarter and the next, and analysts expect sales will grow by -75.8% for the current quarter and -30.8% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +19.2% over the past 5 years. Earnings growth for 2020 is a modest +28.4% while over the next 5 years, the company’s earnings are expected to increase by 20%.